Saturday 17 October 2026
Export AKAN’s income statement to Excel — free account
Akanda Corp.
AKAN Healthcare Drug Manufacturers Specialty & Generic
Akanda Corp.’s revenue for fiscal 2025 (year ended December 2025) was $258,100.00, down 69.2% from fiscal 2024. Insiders bought in the last twelve months.
1.20
0.11
−8.40%
Follow AKAN
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 6,981.98 | 2,240.99 | 85.87 | 9.37 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 1,745,495.50 | 35,754.50 | 3,997.75 | 209.23 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 173 | 46 | 5 | 2 | 2 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.06 | 0.08 | 0.42 | 0.13 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 0 | 0 | 3 | 0 | 1 | 0 | ||||
| Gross margin, % | — | — | — | 0.00 | (2,771.43) | (3.86) | 124.81 | 14.00 | 24.91 | (60.44) | |||||
| EBT | — | — | — | (1) | (2) | (2) | (8) | (4) | (3) | (47) | |||||
| EBT margin, % | — | — | — | 0.00 | (109,552.38) | (5,975.12) | (314.36) | (876.19) | (395.82) | (18,352.15) | |||||
| Net income | — | 0 | — | (1) | (2) | (8) | (12) | (32) | (4) | (47) | |||||
| Depreciation | — | — | — | 0 | 0 | 0 | 4 | 4 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 10.50 | 14.28 | 5,239.40 | 529.63 | 56.53 | 3.75 | ||||
| Earnings | — | — | — | (0.48) | (9,857.57) | (28,127.81) | (2,193.97) | (40,279.03) | (276.36) | (662.22) | |||||
| Cash flow | — | — | — | (0.22) | (6,762.50) | (2,261.07) | (22,938.80) | (1,875.75) | (268.95) | (97.66) | |||||
| Capex | — | — | — | 0.00 | (2,195.50) | (198.79) | (621.80) | 136.13 | (141.76) | (17.91) | |||||
| Free cash flow | — | — | — | (0.22) | (8,958.00) | (2,459.86) | (23,560.60) | (1,739.62) | (410.71) | (115.57) | |||||
| Book value | — | — | — | 0.00 | (25,159.50) | (759.10) | 53,800.40 | (4,786.12) | 288.95 | (174.03) | |||||
| Shares, m | — | — | — | 3 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| P/B | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/Sales | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| EV/FCF | — | — | — | — | 0.00 | 0.00 | (0.11) | (0.17) | 0.08 | (0.68) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (1) | (1) | (7) | (11) | (2) | (4) | (7) | ||||
| Capex | — | — | — | (1) | 0 | (1) | 0 | 0 | (2) | (1) | |||||
| Free cash flow | — | — | — | (1) | (2) | (7) | (12) | (1) | (6) | (8) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | (3) | (4) | (6) | (8) | 1 | (3) | ||||
| Total debt | — | — | — | — | 9 | 9 | 4 | 4 | 0 | 13 | |||||
| Net debt | — | — | — | — | 9 | 6 | 3 | 4 | (3) | 12 | |||||
| Shareholders’ equity | — | — | — | — | (5) | (2) | 27 | (4) | 4 | (12) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (53.82) | (131.99) | (49.56) | (134.94) | (48.90) | (647.13) | ||||
| ROIC | — | — | — | — | (27.44) | (46.82) | (41.94) | 0.00 | (319.90) | (624.17) | |||||
| ROE | — | — | — | 0.00 | 45.72 | 224.83 | (94.40) | (279.79) | (1,830.21) | 1,183.68 | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Jan 0001 · fundamentals updated 2 Oct 2026
Charts ten years each
Akanda Corp. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| APUS Apimeds Pharmaceuticals US, Inc. | $6.6M | — (loss-making) | — | — | n/m | −67.94% (below 0%: shrinking) | — | 0.00% | Compare |
| SNOA Sonoma Pharmaceuticals, Inc. | $5.5M | — (loss-making) | — (loss-making) | +59.55% (above 0%: growing) | n/m | +69.31% (above 0%: growing) | 40.23% | (0.62%) | Compare |
| GELS Gelteq Limited | $4.6M | — | — | — | — | −40.15% (below 0%: shrinking) | — | — | Compare |
| RDHL Redhill Biopharma Ltd. | $4.4M | — (loss-making) | — (loss-making) | −90.32% (below 0%: shrinking) | n/m | −107.31% (below 0%: shrinking) | (7.52%) | 0.00% | Compare |
| YCBD cbdMD, Inc. | $4.0M | 41.2× | — (loss-making) | +20.55% (above 0%: growing) | n/m | +34.80% (above 0%: growing) | 54.69% | (20.36%) | Compare |
| AKAN Akanda Corp. | $3.5M | — | — | — | — | −472.01% (below 0%: shrinking) | (197.87%) | 0.00% | |
| PRFX PainReform Ltd. | $2.6M | — (loss-making) | — (loss-making) | — | n/m | +52.56% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BTAIQ BioXcel Therapeutics, Inc. | $2.3M | — (loss-making) | — (loss-making) | +51.67% (above 0%: growing) | n/m | +51.51% (above 0%: growing) | 87.91% | (5,600.55%) | Compare |
| IMCC IM Cannabis Corp. | $2.2M | — (loss-making) | — (loss-making) | −40.28% (below 0%: shrinking) | n/m | −266.81% (below 0%: shrinking) | 19.83% | (27.54%) | Compare |
| Median of peers | $4.2M | — | — | +20.55% | — | −2.68% | 30.03% | (0.62%) |
Akanda Corp. (AKAN) key facts
- Concern: Akanda Corp.’s revenue for fiscal 2025 (year ended December 2025) was $258,100.00, down 69.2% from fiscal 2024.
- Akanda Corp. (AKAN) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, AKAN traded at $1.20, a market capitalization of $3.5 million.
- Return on equity was 1,183.7% and debt-to-equity -0.70.
- Its Piotroski F-score is 1 out of 9 and its Altman Z-score is −26.39 (distress zone) for fiscal 2025.